Kymera Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Stock-Based Compensation Growth & History (KYMR)
Kymera Therapeutics's stock-based compensation was $59.9M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $59.9M | $4.9M | +8.89% |
| 2024 | 2024-12-31 | $55.0M | $11.9M | +27.58% |
| 2023 | 2023-12-31 | $43.1M | $7.6M | +21.53% |
| 2022 | 2022-12-31 | $35.5M | $10.5M | +42.08% |
| 2021 | 2021-12-31 | $25.0M | $19.8M | +381.16% |
| 2020 | 2020-12-31 | $5.2M | $4.0M | +333.95% |
| 2019 | 2019-12-31 | $1.2M | — | — |
Kymera Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.9M | $3.5M | +22.85% |
| Q1 2026 | 2026-03-31 | $16.0M | $1.8M | +12.46% |
| Q4 2025 | 2025-12-31 | $14.5M | $654,000 | +4.74% |
| Q3 2025 | 2025-09-30 | $15.8M | $898,000 | +6.03% |
| Q2 2025 | 2025-06-30 | $15.4M | $1.1M | +7.50% |
| Q1 2025 | 2025-03-31 | $14.2M | $2.3M | +18.93% |
| Q4 2024 | 2024-12-31 | $13.8M | $2.9M | +26.62% |
| Q3 2024 | 2024-09-30 | $14.9M | $3.2M | +27.88% |
| Q2 2024 | 2024-06-30 | $14.3M | $3.2M | +28.27% |
| Q1 2024 | 2024-03-31 | $12.0M | $2.6M | +27.52% |
| Q4 2023 | 2023-12-31 | $10.9M | $2.0M | +22.33% |
| Q3 2023 | 2023-09-30 | $11.7M | $2.6M | +28.42% |
| Q2 2023 | 2023-06-30 | $11.2M | $1.6M | +16.19% |
| Q1 2023 | 2023-03-31 | $9.4M | $1.5M | +19.20% |
| Q4 2022 | 2022-12-31 | $8.9M | $231,000 | +2.66% |
| Q3 2022 | 2022-09-30 | $9.1M | $1.7M | +22.71% |
| Q2 2022 | 2022-06-30 | $9.6M | $3.9M | +68.04% |
| Q1 2022 | 2022-03-31 | $7.9M | $4.7M | +148.20% |
| Q4 2021 | 2021-12-31 | $8.7M | $6.9M | +374.99% |
| Q3 2021 | 2021-09-30 | $7.4M | $5.1M | +217.70% |
| Q2 2021 | 2021-06-30 | $5.7M | $5.1M | +762.35% |
| Q1 2021 | 2021-03-31 | $3.2M | $2.8M | +754.99% |
| Q4 2020 | 2020-12-31 | $1.8M | — | — |
| Q3 2020 | 2020-09-30 | $2.3M | $2.1M | +894.87% |
| Q2 2020 | 2020-06-30 | $664,000 | — | — |
| Q1 2020 | 2020-03-31 | $371,000 | — | — |
| Q3 2019 | 2019-09-30 | $234,000 | — | — |
Kymera Therapeutics stock-based compensation trends
Over the last five fiscal years, Kymera Therapeutics's stock-based compensation increased from $5.2M to $59.9M, a change of $54.7M. The latest reported quarter, Q2 2026, shows $18.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗